Finding patients for gene-targeted cancer trials
We find the EGFR patients that precision trials need.
BioKindred is building a better way to match people with EGFR lung cancer to the clinical trials that fit them.
About BioKindred
The patients exist.
Drug companies just can't find them.
New cancer drugs target a single gene mutation, so each trial needs a small, exact group of patients. In EGFR lung cancer, about 20,000 Americans are diagnosed each year, but the details that decide who qualifies sit in records spread across different clinics.
What we're building
Patients share their records
Free for patients, and only with their permission.
We check open trials
Each patient gets a personal list of trials they may qualify for.
We introduce the right candidates
With consent, pre-qualified patients are connected with research sites.
The problem we're validating
Eligible EGFR patients are too often missed at the moment they could join a trial.
EGFR trials struggle to find eligible patients, and patients often hear about trials too late. Both sides lose the same short window.
So we're building a better way to match patients with the trials that fit them.
Talk with usMeet the team
The people building BioKindred
Built with the EGFR patient community, backed by clinical-data experience and physician review.
Sharon Dejenu Kassa
Co-founder & CEO
Four years in transaction advisory at Deloitte, EY and Lucy Investment Partners. Built Lung Kindred inside the EGFR community.
Dr. David Lo
Clinical Advisor
Family medicine physician and adjunct professor. Reviews our clinical logic.
Juliet Mirambo
Co-founder & CTO
Technical lead developer and value chain manager at Merck KGaA, built systems that matched drug formulations used in clinical trials.